Melanoma is a rapidly growing and highly metastatic cancer with high mortality rates, for which a resolutive treatment is lacking. Identification of novel therapeutic strategies and biomarkers of tumour stage is thus of particular relevance. We report here on a novel biomarker and possible candidate therapeutic target, the sphingolipid metabolising enzyme acid sphingomyelinase (A-SMase). A-SMase expression correlates inversely with tumour stage in human melanoma biopsies. Studies in a mouse model of melanoma and on cell lines derived from mouse and human melanomas demonstrated that A-SMase levels of expression actually determine the malignant phenotype of melanoma cells in terms of pigmentation, tumour progression, invasiveness and metastatic ability. The action of A-SMase is mediated by the activation of the extracellular signal-regulated kinase, the subsequent proteasomal degradation of the Microphtalmia-associated transcription factor (Mitf) and inhibition of cyclin-dependent kinase 2, Bcl-2 and c-Met, downstream targets of Mitf involved in tumour cell proliferation, survival and metastatisation.
Melanoma is the most aggressive form of skin cancer that hesitates early in the metastatic stage with inauspicious prognosis. 1 Significant advances have been made in understanding its pathophysiology and treatment. Conventional therapies, consisting in surgical resection of lesions and chemotherapy, are thus being complemented by new approaches based on growth factors signalling inhibitors, agents stimulating antitumour immune responses, or adoptive T-cell therapies. 1 The percentage of patients responding to therapy is however still relatively small, with a majority of patients showing short-lived responses. [2] [3] The difficulty in treating melanoma lies mainly in its high degree of heterogeneity 4 , which accounts for the appearance, during melanoma development, of cell populations differing in tumour marker expression, invasive phenotype, drug resistance and immunogenicity. 5 Heterogeneity also impacts on the melanoma staging and prognosis. Melanoma stage is still defined by clinical criteria. 6 However, significant recent developments are leading to a classification by molecular criteria. 7 A better definition of the melanoma molecular signature will be instrumental to both early diagnosis and efficient and tailored treatments.
We identify an unexpected role for the sphingolipidmetabolising enzyme acid sphingomyelinase (A-SMase) that opens new perspectives in terms of both its use as a melanoma biomarker and as a therapeutic target. A-SMase is activated in response to various proinflammatory and proapoptotic stimuli; [8] [9] [10] [11] [12] it contributes to apoptotic death of tumour cells induced by different antineoplastic treatments 13 and has a role in immunity and inflammation, regulating macrophages and dendritic cells differentiation/function or cytokines secretion. [14] [15] [16] We now report that A-SMase is also a key determinant of melanoma cell behaviour. A-SMase levels of expression correlate with melanoma grade in human biopsies. Studies in vivo in a mouse model of melanoma and in vitro on human and mouse melanoma cells demonstrated that such correlation is not coincidental. A-SMase levels of expression actually determine the malignant phenotype of melanoma cells in terms of pigmentation, tumour progression and metastatic capacity. We have characterised the molecular pathway responsible for A-SMase effect and found a significant role being played by the Microphtalmia-associated transcription factor (Mitf), a gene associated with familial and sporadic melanoma. [17] [18] [19] We found that Mitf regulation by A-SMase is mediated by the activation of the extracellular signal-regulated kinase (ERK) responsible for Mitf degradation by proteasome. The loss of A-SMase during melanoma progression accounts for the upregulation of Mitf and its downstream targets cyclin-dependent kinase 2 (CDK2), Bcl-2 and c-Met.
Results
A-SMase expression correlates with melanoma progression. A-SMase expression was evaluated by immunohistochemistry in sections from human bioptic specimens of melanomas at various stages (Supplementary Table S1 ). Enzyme expression was higher in benign nevi than in primary melanomas, and further reduced in the lymph-node metastases ( Figure 1a ). Quantitative analyses of results from several samples carried out using two analysis softwares, ImageJ (Figure 1b) and AxioVision 4 (Supplementary Figures S1A and B) , 20, 21 indicate that the differences in A-SMase expression among the groups of specimens are significant. The different expression of A-SMase in primary melanomas and metastases was confirmed further by immunofluorescence analyses (Figures 1c and d) . Similar results were observed in an in vivo model of mouse melanoma in which we injected sub-cutaneously (s.c.) in C57BL/6 mice B16-F1 and B16-F10 murine cells; the former was unable to generate metastases, whereas the latter was able to. 22 Expression of A-SMase was higher in B16-F1 melanoma, further suggesting a relationship between melanoma propensity to yield metastases and A-SMase expression (Figures 1e and f) . Figure S2) were analysed for A-SMase expression and activity (Figures 2a and b) . In parallel, we characterised also four human melanoma cell lines GR4, Gian-mel, Det-mel and MSR3, 23 which significantly differ in terms of expression/activity of A-SMase (Figures 2d and e) .
As the relationship between melanoma pigmentation and progression has long been of research interest, we first aimed at examining the effect of A-SMase on melanin content. We found an inverse correlation between A-SMase expression/ activity and melanin content (Figures 2a-c (Figure 2g ), thus supporting the role of A-SMase in the modulation of melanoma cell phenotype and confirming previous studies showing that melanin in melanocytes is significantly decreased by ceramide, the main product of A-SMase. 24 The tight relationship between ceramide metabolism and melanogenesis is demonstrated further by the similarity in the pattern of ceramide content in B16-B9 and B16-W6_pSIL10 cells, while differing significantly in B16-W6 (Supplementary Figure S4B) .
A-SMase expression by melanoma cells inhibits tumour formation and growth. We evaluated the tumourigenic capacity of the B16 clones in vivo following single-cell s.c. injection into C57BL/6 mice. A high percentage of mice injected with B16-B9 and B16-W6_pSIL10 developed detectable tumours (B16-B9 ¼ 83 ± 3%; B16-W6_pSIL10 ¼ 70 ± 4%) within 60 days (Figure 3a ). In contrast, tumours grew only in 18±2% of mice injected with B16-W6 cells. Consistently, B16-B9 and B16-W6_pSIL10 generated a significantly higher number of large colonies than that generated by B16-W6 cells when tested in vitro for their anchorage-independent growth capacity (Supplementary Figure S5A and Supplementary  Table S2) .
We next evaluated the effect of A-SMase on melanoma cell proliferation. In vitro, proliferation of B16-B9, B16-W6 and B16-W6_pSIL10 cells correlated inversely with A-SMase expression both in normal serum conditions and after serum deprivation (Supplementary Figures S5B and C) . In vivo, the growth of B16-W6 tumours were slower than that of B16-B9 and B16-W6_pSIL10, resulting in an increase of the median survival, particularly in the first 21 days after injection (median of survival: B16-W6 ¼ 33 days; B16-B9 ¼ 21; B16-W6_pSIL10 ¼ 25.5 days; B16-W6 versus B16-B9, Po0.0001; B16-W6 versus B16-W6_pSIL10, Po0.01) (Figure 3b) . Interestingly, the expression of A-SMase by the B16 tumours decreased with time regardless of the clone (Figures 3c and d) and this was associated to an increased proliferation rate. At later stages, when A-SMase expression was very low in all clones, their proliferation rates became super-imposable.
B16-B9 and B16-W6_pSIL10 tumours expressed high levels of Ki67, a marker of proliferative cells (Figure 3d ), and showed morphological aspects typical of rapid growth phase tumours ( Figure 3e ) with proliferating cells highly represented even in the inner mass, indicating that A-SMasedeficient cells are able to proliferate even in conditions of nutrition deprivation and low oxygen. By contrast, in the slowgrowing B16-W6 tumour proliferating cells resided only around blood vessels, identified by the expression of CD31 (Figure 3e ).
We finally examined the effect of A-SMase expression on melanoma apoptosis in vivo, using flow cytometry after staining of tumours with Annexin V. The higher expression of A-SMase in B16-W6 tumour correlated with an increased number of apoptotic cells when compared with B16-B9 and B16-W6_pSIL10 (Figure 3f ), according to the apoptogenic role of A-SMase.
The results obtained in human Det-mel and MSR3 cells were in line with those of mouse models. The reduced expression of A-SMase in Det-mel correlated with an increased anchorageindependent growth capacity (Figure 4a and Supplementary  Table S2 ) and proliferation rate with respect to A-SMase highly expressing MSR3 (Figures 4b and d) ; consistent with a role of A-SMase in melanoma cell behaviour the overexpression of A-SMase in Det-mel cells reduced significantly their proliferation (Figure 4c) .
A-SMase expression by melanoma cells inhibits their migratory, invasive and metastatic ability. The migratory and invasive properties of B16-B9, B16-W6 and B16-W6_pSIL10 clones were then examined. In vitro, migration, invasion and transmigration of B16-W6 cells were significantly reduced with respect to B16-B9 and B16-W6_pSIL10 cells (Supplementary Figures S6A and B) . Thus, A-SMase expression correlates inversely with metastatic potential. In vivo, this correlation was evaluated by injecting B16 clones labelled with the fluorescent dye CFSE into the tail vein of mice. The presence of melanoma cells in lungs was evaluated at 96 h by flow cytometry and quantitative real-time PCR (qPCR). B16-B9 and B16-W6_pSIL10-injected mice displayed a significantly higher number of fluorescent cells at the pulmonary level than B16-W6-injected ones (Figure 5a) . Likewise, the specific melanoma markers Mel-A and Pax-3, expressed by all clones at similar degrees (Supplementary Figure S6C) , were more abundant in lungs of B16-B9 and B16-W6_pSIL10-injected animals (Figure 5b) . After 14 days, we analysed lung metastases by counting the number of nodules. Lung of mice injected with B16-B9 and B16-W6_pSIL10 cells showed a 100-and 60-fold increase of nodules, respectively, compared with those of mice injected with B16-W6, where nodules were virtually undetectable (Figure 5c 
A-SMase downregulation in melanoma cells affects the expression of metastasis-related genes. We evaluated whether A-SMase expression affects the molecular signature of murine melanoma clones using a qPCR array targeting 84 genes known to be involved in tumour growth and metastasis (Supplementary Table S3 ). B16-F10 murine cells were used as a positive control because they are a model with high metastatic potential. 22 These cells displayed A-SMase expression/activity levels and melanin content comparable to B16-B9 and B16-W6_pSIL10 cells ( Supplementary  Figures S7A-C) . qPCR array data are summarised in the correlation and linear regression analysis of Supplementary Figure S6D , where the gene expression ratios (DCt) in three experiments are presented. The gene expression levels measured in each array strongly correlated, the Pearson correlation coefficients for each array pair comparison being 40.90 (Po0.001). The paired comparisons of B16-W6_pSIL10, B16-B9 and B16-F10 appear 'tighter' and closer to the respective linear regression fit line than data resulting from their comparisons with B16-W6. These monotonic relationships between B16-W6_pSIL10, B16-B9 and B16-F10 cells indicate a very high degree of gene expression homology, whereas B16-W6 cells do differ.
The expression of several genes did not change in B16-W6_pSIL10 cells when compared with B16-W6 (less than twofold change) (heat-map in Supplementary Figure S6E) . Similar results were obtained with B16-B9 and B16-F10 cells. Several other genes, common to B16-W6_pSIL10, B16-B9 and B16-F10, however, showed at least a twofold change versus B16-W6 (Figure 5d ). Among these we found 12 genes whose expression was similar in B16-B9, B16-F10 and B16-W6_pSIL10, suggesting that their regulation is tightly coupled to A-SMase signalling (Figure 5d ). Of interest, the protooncongene c-Met, highly expressed in melanomas and linked to metastatic potential, 25 was upregulated by five folds.
A-SMase modulates Mitf and its downstream signalling targets to regulate cell malignant properties. The increased c-Met expression in melanoma cells occurs at transcriptional levels requiring Mitf, a master regulator gene of melanocyte development and melanoma development and progression. 26 We thus investigated the relationship between A-SMase and Mitf. As shown by immunohistochemical analysis of tumours, Mitf expression was regulated by A-SMase; in low A-SMase-expressing B16-B9, B16-W6_pSIL10 cells it was upregulated with respect to B16-W6 cells (Figure 6a ). Of importance, Mitf expression increased in B16-W6 tumours at late stage of progression (Figure 6a) , that is when A-SMase became downregulated, with a clear inverse relationship (Figure 6b) , consistent with the role of Mitf on melanoma growth. 27, 28 Similar results were obtained in vitro in murine cells including B16-F10, as well as in human cells (Figures 6c and d and Supplementary Figure  S7D) ; notably, Mitf silencing did not affect A-SMase expression (Figure 6e and Supplementary Figure S8A) . We then investigated how A-SMase regulates Mitf. Ceramide induces Mitf phosphorylation and its degradation by proteasome through ERK activation. 24 Consistently, phosphorylated ERK (pERK) was significantly increased in B16-W6 and B16-B9/B16-W6_pSIL10 transfected with A-SMase when compared with untransfected B16-B9/B16-W6_pSIL10 and B16-F10 cells (Figure 6c and Supplementary Figure S7D) . The correlation between pERK and Mitf was also observed in Det-mel and MSR3 cells (Figure 6d) . The effect of A-SMase was inhibited by PD98059, an inhibitor of MAP kinases (Figure 6f and Supplementary Figure S8B) . pERK was not affected by Mitf silencing confirming that MAPK activity is upstream Mitf (Figure 6c and Supplementary Figure S8A) . Moreover, the proteasome inhibitor MG132 blocked the effect of A-SMase, indicating that A-SMase-induced ERK activation coupled to Mitf degradation (Figure 6f) .
Finally, we investigated whether Mitf regulation by A-SMase led to changes in Mitf signalling. Whenever Mitf was upregulated, that is in the low A-SMase-expressing cells, the proliferation marker CDK2, the apoptosis modulator Bcl-2, the melanin-synthesising enzyme Tyr and the pro-metastatic c-Met were upregulated (Figures 7a-c) . Of importance, A-SMase overexpression or Mitf silencing into B16-B9 and B16-W6_pSIL10 cells reduced the expression of all Mitf targets to levels similar to those found in B16-W6 cells (Figures 7a-c) and specifically inhibited proliferation, survival and migratory ability of tumour cells (Figures 7d-f and Supplementary Figures S9A-C) .
Discussion
In this study we have identified and characterised a key pathophysiological role of A-SMase. To date knowledge on the role of this enzyme in tumours was limited to its ability of mediating apoptotic cell death in response to chemotherapeutic drugs and radiation. 13 Our results expand significantly the role of A-SMase in melanoma showing that it controls tumour ability to grow, invade and metastasise. Malignant melanomas are composed of subpopulations of cells with a wide range of phenotypic variations, especially in terms of pigment synthesis. 29 In melanomas it is possible to identify cells with different grade of pigmentation and also cells unable to generate melanin (amelanotic melanoma). 29 Multiple mechanisms to explain amelanosis have been suggested but appropriate studies to compare outcomes of amelanotic versus pigmented melanomas have not been performed. 30 On the other hand, it was observed that more pigmented melanoma cells had an enhanced ability to metastasise and that pigmented cell lines are more tumourigenic, invasive and metastatic than the non-pigmented ones. [31] [32] [33] Recently, the melanocytic differentiation programme has been suggested to predispose melanomas to metastasis after oncogenic transformation. 34 Although the correlation between pigmentation and malignancy is not clearly established, our finding that melanoma clones showed an inverse correlation between A-SMase and melanin content indicates a key role of A-SMase in melanogenesis and possibly melanoma development. In this respect, the central role of the enzyme in determining melanoma cell fate is manifested by what we found in human specimens: A-SMase expression corresponds inversely with tumour malignancy, being lower in metastases with respect to benign lesions. We investigated this aspect in vivo and found that A-SMase expression in melanoma cells decreased progressively with time, an event associated with an increased tumour growth and decreased animal survival. A possible explanation of this event is that microenvironmental factors act on melanoma cells, thus modulating A-SMase during tumour growth. Indeed, it has been shown that tumour microenvironment can modulate the expression patterns of cancer cells involved in proliferation, apoptosis and cell motility. 35, 36 Although it is tempting to speculate a crosstalk in tumour microenvironment inducing changes on A-SMase, further studies are needed to understand fully what may have occurred in our system.
The correlation between A-SMase expression and tumour regression we now describe prompted us to propose A-SMase as a key factor in melanoma. The involvement of A-SMase in several critical phases of melanoma cell behaviour from proliferation to migration and ability to metastasise is intriguing and the possibility that the enzyme may be a new useful molecular biomarker of disease progression deserves to be investigated.
The broad role of A-SMase in tumour pathogenesis, identified by us, indicates also that the enzyme is at the crossroad of key pathways in tumourigenesis. This aspect has clear potential in therapeutic perspective and we have characterised it further.
To date analyses of signalling pathways dependent on A-SMase have concentrated mainly on pro-apoptotic effects or in the regulation of the immune system. 10, 11, 15, [37] [38] [39] None of its already identified targets can conceivably explain the role of A-SMase in melanoma.
We thus carried out an extensive study of potential effectors of A-SMase in melanoma. The gene expression profile of B16 clones revealed that several factors were differentially expressed depending on the levels of A-SMase. Of particular interest is the inhibition of Mitf expression by A-SMase in tumours, which leads to inhibition of tumour growth, cell proliferation/differentiation and metastatic ability.
In line with previous reports on the modulation of Mitf by ceramide, 24 we demonstrated that A-SMase induces the proteasomal degradation of Mitf through a sustained activation of the MAPK ERK. The role of Mitf in melanocytes/melanomas has been object of debate. This transcription factor is expressed by nearly all melanomas, although with a high variability across specimens. 40, 41 Mitf is associated with key cellular pathways critical for tumourigenesis. 42 In particular, in agreement with our results, many published data are consistent with a role of Mitf in promoting proliferation/ progression/invasiveness/resistance to chemotherapy, in suppressing senescence and in forming metastases. 28, 32, 40, [43] [44] [45] [46] [47] [48] [49] [50] [51] In addition, Mitf expression is enhanced in B20% of human metastatic melanomas and in a genetic mouse model of melanoma. 40, 41 Taken together, these observations provide compelling support for a key role of Mitf in favouring melanoma development. However, different reports suggest for Mitf an anti-melanoma activity. 28, 49, 52 A model proposes Mitf as a rheostat to control melanoma cell phenotype, allowing a switch from poorly differentiated and highly metastatic cells to fastgrowing progeny. 49 It has been recently shown that the transient loss of Mitf decreases melanoma cell growth in culture, but favours the development of melanomas in mice. 52 These in vivo data are in apparent contrast with our results. However, it should be noted that cells in which Mitf was constitutively silenced did not form tumours in vivo, indicating that Mitf re-expression is required to melanoma growth. 52 It has been thus hypothesised that Mitf-depleted cells are able to reexpress Mitf giving rise to fast-growing cells and that melanomas contain spontaneously a small population of Mitfnegative cells, which can readily generate a Mitf-expressing progeny with fast-growing properties. 28, 52 In agreement with this model, we found that Mitf expression increases during tumour growth. In addition, the inverse correlation between Mitf and A-SMase observed in tumours prompted us to suggest the inhibition of A-SMase as a signal allowing the expression of Mitf and the subsequent increase of tumour growth.
Among the factors we found regulated by A-SMase are CDK2, Bcl2 and c-Met, which are involved in tumoural cell invasion, apoptosis and proliferation, respectively. 26, 42, 50 They are downstream targets of A-SMase-Mitf axis, likely modulating cell growth/function. Thus, the A-SMase-induced inhibition of Mitf and its signalling may well explain why this enzyme is implicated in so many diverse phases of melanoma progression (Figure 8 ). The molecular signalling we describe here for A-SMase has therapeutic implications. Inhibition of CDK2, Bcl2 and c-Met have all been suggested as therapeutic approaches for melanoma treatment. 53, 54 In view of its centrality to these and other tumour-related pathways A-SMase might become an interesting therapeutic target exploiting the synergism of multiple significant pathways. The prognostic and therapeutic relevance of A-SMase is consistent with preclinical studies showing a role of ceramide in delaying tumour growth. 55, 56 Recently, the use of adenoviral-mediated gene transfer of A-SMase has been proposed as a candidate therapy for Niemann Pick disease. 57 In view of the reduced expression of A-SMase in metastatic melanoma it would be important to address whether such gene transfer is applicable also to melanoma, in order to set up combinatorial therapeutic strategies with classical chemotherapy or the novel monoclonal-based therapies. Figure S2) . Figure S2B) , their specificity was tested by the qPCR analysis of off-target gene expression (Supplementary Figures S2C and  D) . The smpd1 siRNA1 sequence, which gave the best silencing (Supplementary Figure S2B) , was used to create a short hairpin sequence (shRNA) to be cloned into a pSilencer 4.1-CMV neo vector. Transfection of the shRNA vector was performed in B16-W6 cells using Fugene transfection reagent according to the manufacturer's protocol. Approximately 30 colonies resistant to the antibiotic G418 (500 mg/ml) were tested for A-SMase silencing through FACS analysis. The selected clone (here referred to as B16-W6_pSIL10) showed an 80% decrease in A-SMase expression when compared with B16-W6 clone (Supplementary Figure S2E) . B16-W6 cells transfected with the pSilencer 4.1-CMV neo Negative Control plasmid supplied with the kit were also generated. Immunohistochemistry and immunofluorescence. For immunohistochemistry and immunofluorescence of formalin-fixed, paraffin-embedded sections the slides were first dewaxed in xylene and hydrated with 2% bovine serum albumin (BSA)-PBS and then incubated overnight at 4 1C with primary antibody (Ab) for A-SMase. 9, 11 For immunohistochemistry, slides were incubated with the biotinylated secondary Ab followed by incubation with steptavidin horseradish peroxidase-conjugated, after washing. Reactions were developed using 3,3-diaminobenzidine (DAB; Sigma-Aldrich) and sections counterstained with haematoxylin, dehydrated with a graded series of ethanol, cleaned with xylene, mounted and visualised by light microscopy. For immunofluorescence, after washing, slides were incubated with a secondary Ab conjugated with Alexa Fluor 546. Images were acquired with a Leica DMI4000B microscope.
B16-
For histochemistry and immunohistochemistry of murine melanomas, tumours were induced by s.c. injection of B16 cells, removed when they reached 7 mm on either diameter, embedded in OCT and sectioned. Sections of 5-6 mm of thickness were previously air-dried and first stained with haematoxylin-eosin for the initial morphological evaluation.
For immunohistochemistry the air-dried sections were treated in 0.3% H 2 O 2 in methanol to quench endogenous peroxidase activity, and incubated overnight at 4 1C with the specific primary Abs against A-SMase, Ki67 and CD31. For secondary Ab staining and image visualisation the procedure followed was as above.
For cells immunofluorescence studies, cells were seeded on glass coverslips coated with poly-L-lysine. After their adhesion, cells were fixed for 10 min with 4% paraformaldehyde at room temperature, incubated for 5 min with 1% glycine-PBS, and blocked for 30 min with 10% goat serum, 1% BSA, 0.1% saponin in PBS at room temperature. Cells were then incubated with specific primary Abs in 1% BSA, 0.1% saponin in PBS for 1 h at room temperature. For fluorescent detection appropriate secondary Ab conjugated with Alexa Fluor 546 was used. Images were acquired with a Leica DMI4000B microscope. 9 In all experiments, the secondary Ab alone was assessed as a negative control.
In vivo metastasis assay. C57BL/6 mice (eight animals per group) were injected in the tail vein with 1 Â 10 5 cells loaded with 10 mM carboxyfluorescein succinimidyl ester (CFSE). After 96 h, mice were killed and lungs were removed and dispersed to cells. The presence of melanoma fluorescent cells was detected by flow cytometry using a Fluorescence-activated Cell Sorter (FC500 Dual Laser system; Beckman Coulter), by comparison with lung cells obtained from mice injected with vehicle and also performing qPCR for the specific markers of melanoma cells Mel-A and Pax-3. 59 For the evaluation of macrometastasis nodules, mice were injected as above and killed after 14 days. Lungs were scored under a dissecting microscope for the number of metastatic foci on the surface.
RT
2 profiler PCR array. Total RNA was isolated and purified from B16-W6, B16-W6_pSIL10, B16-B9 and B16-F10 cells using SABiosciences RT2 qPCRGrade RNA Isolation Kit (Qiagen). cDNA was transcribed using a SABiosciences RT 2 First Strand Kit following the manufacturer's instructions. For PCR array experiments, the SABiosciences mouse tumour metastasis RT 2 Profiler PCR array (catalog number PAM-028) and the SABiosciences RT 2 SYBR Green qPCR Mastermix were used to simultaneously examine the mRNA levels of 84 genes closely associated with tumour metastasis and 5 'housekeeping genes' (Supplementary Table S3 ). Arrays were performed on Roche LightCycler 480 Instrument. Ct values for housekeeping genes were monitored for consistency between the arrays and the negative controls ensured a lack of DNA contamination and set the threshold for the absent/present calls. Data were normalised using multiple housekeeping genes and analysed by comparing 2 À DDCt of the normalised sample using the software supplied on the SABiosciences website (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). The resulting values were reported as fold change; only genes showing twofold or greater change were considered. Matrix2png software version 1.2.2 (http://www.chibi.ubc.ca/matrix2png/) was used to create the heat-maps. 60 Statistical analysis. Upon verification of normal distribution, statistical significance of raw data between the groups in each experiment was evaluated using unpaired Student's t-test or ANOVA followed by the Bonferroni post-test. Kaplan-Meier data were analysed with the multiple comparison survival curve method using the Log-rank (Mantel-Cox) test. Results are expressed as means ± standard error of the mean (S.E.M.).
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